These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 6409615)
1. Intravesical thiotepa prophylaxis of superficial bladder cancer. A follow-up study. Fosså SD; Miller A; Stenwig AE Eur Urol; 1983; 9(4):207-10. PubMed ID: 6409615 [TBL] [Abstract][Full Text] [Related]
2. The effect of intravesical thiotepa on tumour recurrence after endoscopic treatment of newly diagnosed superficial bladder cancer. A further report with long-term follow-up of a Medical Research Council randomized trial. Medical Research Council Working Party on Urological Cancer, Subgroup on Superficial Bladder Cancer. Br J Urol; 1994 Jun; 73(6):632-8. PubMed ID: 8032829 [TBL] [Abstract][Full Text] [Related]
3. [Preventive value of intravesical thiotepa on the recurrence of Ta-T1 vesical tumors treated by conservative surgery. Apropos of 247 cases a mean follow-up of 88 months]. Gilloz A; Sauvage I; Gremillet E; Héritier P; Richard A; el Hajj E; Diez-Yanguas J J Urol (Paris); 1987; 93(4):197-202. PubMed ID: 3119728 [TBL] [Abstract][Full Text] [Related]
4. Intravesical therapy comparing BCG, adriamycin, and thiotepa in 200 patients with superficial bladder cancer: a randomized prospective study. Martinez-Pineiro JA; Jimenez León J; Martinez-Pineiro L; Fiter L; Mosteiro JA; Navarro J; García Matres MJ; Cárcamo P Prog Clin Biol Res; 1989; 310():237-52. PubMed ID: 2505269 [TBL] [Abstract][Full Text] [Related]
5. Thiotepa versus adriamycin versus cis-platinum in the intravesical prophylaxis of superficial bladder tumors. Llopis B; Gallego J; Mompó JA; Boronat F; Jiménez JF Eur Urol; 1985; 11(2):73-8. PubMed ID: 3924624 [TBL] [Abstract][Full Text] [Related]
6. A trial of prophylactic thiotepa or mitomycin C intravesical therapy in patients with recurrent or multiple superficial bladder cancers. Flanigan RC; Ellison MF; Butler KM; Gomella LG; McRoberts JW J Urol; 1986 Jul; 136(1):35-7. PubMed ID: 3086575 [TBL] [Abstract][Full Text] [Related]
7. [Superficial bladder cancer: prophylaxis of recurrence and progression]. Miyanaga N; Akaza H; Koiso K Gan To Kagaku Ryoho; 1991 Nov; 18(14):2369-74. PubMed ID: 1719939 [TBL] [Abstract][Full Text] [Related]
8. [Use of thiotepa, in local instillation, as a prophylactic treatment for recurrence of superficial tumors of the bladder]. Toulouse J; Bouffier B; Etievent JP; Bittard M J Urol (Paris); 1983; 89(2):85-9. PubMed ID: 6408192 [TBL] [Abstract][Full Text] [Related]
9. Thiotepa bladder instillations: therapy and prophylaxis for superficial bladder tumors. Veenema RJ; Dean AL; Uson AC; Roberts M; Longo F J Urol; 1969 May; 101(5):711-5. PubMed ID: 4976352 [No Abstract] [Full Text] [Related]
10. [Intravesical BCG, mitomycin-C and thiotepa in the prevention of bladder tumor recurrence after operation]. Wang SH Zhonghua Wai Ke Za Zhi; 1992 Jul; 30(7):410-2, 443-4. PubMed ID: 1301342 [TBL] [Abstract][Full Text] [Related]
11. The role of intravesical thiotepa in the management of superficial bladder cancer. National Bladder Cancer Collaborative Group A. Cancer Res; 1977 Aug; 37(8 Pt 2):2916-7. PubMed ID: 406040 [TBL] [Abstract][Full Text] [Related]
12. Intravesical thiotepa in prevention of recurrence of bladder tumour. Ghosal SK; Sen DK J Indian Med Assoc; 1980 Nov; 75(9):173-4. PubMed ID: 6785360 [No Abstract] [Full Text] [Related]
13. Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer. Martínez-Piñeiro JA; Jiménez León J; Martínez-Piñeiro L; Fiter L; Mosteiro JA; Navarro J; García Matres MJ; Cárcamo P J Urol; 1990 Mar; 143(3):502-6. PubMed ID: 2106041 [TBL] [Abstract][Full Text] [Related]
14. Comparisons of placebo, pyridoxine, and topical thiotepa in preventing recurrence of stage I bladder cancer. Byar D; Blackard C Urology; 1977 Dec; 10(6):556-61. PubMed ID: 414402 [TBL] [Abstract][Full Text] [Related]
15. The effect of intravesical thiotepa on the recurrence rate of newly diagnosed superficial bladder cancer. An MRC Study. MRC Working Party on Urological Cancer. Br J Urol; 1985 Dec; 57(6):680-5. PubMed ID: 2867800 [TBL] [Abstract][Full Text] [Related]
16. Intravesical 4'-epi-doxorubicin (epirubicin) versus bacillus Calmette-Guérin. A controlled prospective study on the prophylaxis of superficial bladder cancer. Melekos MD; Chionis HS; Paranychianakis GS; Dauaher HH Cancer; 1993 Sep; 72(5):1749-55. PubMed ID: 8348504 [TBL] [Abstract][Full Text] [Related]